In one such trial, T-DM1 was compared with standard dosing of trastuzumab every 3 weeks plus docetaxel every 3 weeks. Objective response rates were comparable and grade 3 or4 adverse events were ...

PurposeTrastuzumab emtansine (T-DM1), an antibody–drug conjugate comprising the cytotoxic agent ... Effects of trastuzumab emtansine (T-DM1) on QT interval and safety of pertuzumab plus T-DM1 in ...